N/A
Manufactured by Viatris Specialty LLC
45,997 FDA adverse event reports analyzed
Last updated: 2026-04-14
CARISOPRODOL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Viatris Specialty LLC. The most commonly reported adverse reactions for CARISOPRODOL include PAIN, COMPLETED SUICIDE, DRUG INEFFECTIVE, NAUSEA, HEADACHE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CARISOPRODOL.
Out of 18,847 classified reports for CARISOPRODOL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 45,997 FDA FAERS reports that mention CARISOPRODOL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PAIN, COMPLETED SUICIDE, DRUG INEFFECTIVE, NAUSEA, HEADACHE, ANXIETY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Viatris Specialty LLC in connection with CARISOPRODOL. Always verify the specific product and NDC with your pharmacist.